Latest from CannIntel
DEA Rescheduling Bet May Leave THCA Hemp Loophole Wide Open
Moving cannabis to Schedule III could inadvertently cement legal status for intoxicating hemp products under the 2018 Farm Bill.
Circuit Judge Lifts Cannabis Injunction in Florida Licensing Dispute
Florida's Second District Court of Appeal vacated a preliminary injunction blocking state cannabis licenses, clearing path for dormant applications.
DEA Marijuana Rescheduling Delay Raises Stakes for Industry and Patients
Administrative roadblocks push final rule timeline past November, threatening tax relief and research access.
Cannabis Shows Behavioral Benefits in Dementia Patients, New Study Finds
Research links cannabinoid therapy to reduced agitation and improved sleep in nursing-home residents with dementia.
Psychedelics, Cannabis, GLP-1s Face Converging Policy Shifts in 2026
Three substance classes—psychedelics, cannabis, and GLP-1 drugs—are navigating simultaneous federal and state regulatory changes this summer.
California Hemp Law Restricts Therapeutic Products, Advocates Say
AB 45's new potency caps block patient access to hemp-derived therapeutics, advocacy groups argue, while lawmakers say the measure protects consumers.
The CannIntel legalization tracker
What growers are reading this week
Hop latent viroid is now the costliest pathogen in commercial cannabis
LED vs HPS in 2026: the calculation has changed
The germination method that consistently pops 95% of seeds
Outdoor soil prep for 2026: amend the holes, not the transplants
Trending strains right now
The CannIntel topic hubs
Strain comparisons
Best cannabis strains, by category
The cannabis glossary
The cannabis economy
Canopy Growth Faces August Earnings Amid German Policy Shift, Insider Sales
The Canadian cannabis producer confronts a tightening German market and executive stock disposals ahead of its quarterly report.
Florida Medical Marijuana Sales Hit 12.1B mg of THC in 2026
State's medical program moved 4.1 million ounces through first half of 2026, signaling continued growth in the nation's third-largest medical market.
The Q1 2026 MSO earnings: who's surviving compression, who isn't
Wholesale prices keep grinding lower. We read every earnings call so you don't have to.
The craft cannabis economics that the MSOs cannot match
Small-batch cultivators are gaining share in mature markets. Here's the cost structure behind why.
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.